The EZH2 inhibitor tazemetostat moderately impacted the syngeneic xenografts tumor growth and enhanced the efficacy of taxane chemotherapy significantly reducing overall tumor size and increasing intratumoral T cells. This evidence concerns the gene EZH2 and neoplasm.